Portage Biotech Inc. (PRTG) - Quarterly EPS earnings growth

Official company branding of Portage Biotech (PRTG)

Quarterly net income per share growth demonstrates the potential for Portage Biotech Inc. (PRTG) to scale R&D through global licensing. The current value of 78.40 reflects the metric's baseline. The development of a multi-target immuno-oncology ecosystem creates a foundation for combination therapy. However, liquidity shortages and the freezing of research are forcing management to seek buyers for intellectual assets or explore merger options.

Portage Biotech (PRTG) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 09/04/2025

Analytical breakdowns for Portage Biotech Inc.

- market value and analyst target forecast:
Price Chart Portage Biotech|PRTG - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization Portage|PRTG - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Portage Biotech|PRTG - Total Stockholders' Equity|Market Value to Book Value Ratio portagebiotech.com|PRTG - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Portage Biotech Inc.|PRTG - Long-Term Liabilities to Capital|Short-Term Debt to Capital Portage Biotech Inc.|PRTG - Company Total Indebtedness|Debt to Book Value Portage|PRTG - Long-Term Debt|Company Current Liabilities Portage Biotech|Quick Liquidity Indicator portagebiotech.com
- earnings and market multiples details:
PRTG - Profit After Payment of Taxes|Projected Future Earnings Portage Biotech Inc.|PRTG - Company Value to Net Income|Forward P/E Multiple Portage|PRTG - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Portage|PRTG - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Portage Biotech|PRTG - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months portagebiotech.com|PRTG - Earnings per share trend in current year|Expected earnings per share growth for next year Portage Biotech Inc.
- sales volume and revenue indicators:
PRTG - Company Total Revenue|Company Projected Revenue Portage Biotech|PRTG - Price-to-Sales Ratio|Price-to-Projected Revenue Ratio Portage
Fundamental company analysis:Portage Biotech, PRTG
Manufactured product of Portage Biotech Corp

Quarterly EPS growth measures the dynamics of net profit per share, allowing investors to assess business scaling efficiency and the pace of value generation. Analyzing the current quarterly EPS trend on the GURU.Markets platform reveals the impact of the radical reduction in operating expenses at Portage Biotech Inc. (PRTG) as part of its strategy to preserve capital and identify monetization pathways for its oncology pipeline.

Analysis of competing companies

Incyte (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months HCM|NUVB (Nuvation Pharma) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Day One Biopharmaceuticals Inc (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Therapeutics (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Biopharma IMAB|Fennec Pharma - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year corbuspharma.com CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring, Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla, Inc.)|LIXT (Lixte Biotechnology, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months CLRB (cellectar.com)|BioLineRx - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months CANF (Can-Fite BioPharma Ltd)|APRE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Kazia Therapeutics Limited (KZIA)|Year-over-year earnings per share growth for the last twelve months Silexion Therapeutics Corp.|NCNA: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CMRX|Quarterly EPS earnings growth Cyclacel Pharmaceuticals, Inc. (CYCC)|Year-over-year earnings per share growth for the last twelve months G1 Therapeutics GTHX|KRON (Kronos Bio Corporation) - Year-over-year net earnings per share trend for the last twelve months|KTRA: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months oncternal.com